Theravance Biopharma, Inc.
US ˙ NasdaqGM ˙ KYG8807B1068

SecurityTBPH / Theravance Biopharma, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership983,615 shares
Latest Disclosed Value $ 15,959,902
Dimensional Fund Advisors Lp reports 14.51% increase in ownership of TBPH / Theravance Biopharma, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 983,615 shares of Theravance Biopharma, Inc. (US:TBPH) valued at $15,964,071 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 858,957 shares of Theravance Biopharma, Inc.. This represents a change in shares of 14.51% during the quarter. The current value of the position is $16,023,088 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 983,615 124,658 14.51 15,960 -0.70 0.0033
2026-02-12 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 858,957 92,253 12.03 16,072 43.58 0.0034
2025-11-12 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 766,704 44,634 6.18 11,193 40.53 0.0024
2025-08-12 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 722,070 78,232 12.15 7,965 38.52 0.0018
2025-05-13 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 643,838 90,125 16.28 5,751 10.36 0.0014
2025-02-13 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 553,713 95,304 20.79 5,211 41.04 0.0013
2024-11-07 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 458,409 128,228 38.84 3,695 31.98 0.0009
2024-08-09 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 330,181 91,679 38.44 2,800 30.86 0.0007
2024-05-10 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 238,502 105,318 79.08 2,139 42.89 0.0006
2024-02-07 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 133,184 61,564 85.96 1,497 142.63 0.0004
2023-11-09 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 71,620 16 0.02 617 -16.62 0.0002
2023-08-09 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 71,604 71,604 741 0.0002
2017-02-09 2016-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -43,018 -100.00 0 -100.00
2016-11-10 2016-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 43,018 0 0.00 1,558 59.63 0.0008
2016-08-09 2016-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 43,018 -474 -1.09 976 19.46 0.0006
2016-05-13 2016-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 43,492 -30 -0.07 817 14.59 0.0005
2016-02-10 2015-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 43,522 20,004 85.06 713 176.36 0.0004
2015-11-13 2015-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 23,518 -1,088 -4.42 258 -19.37 0.0002
2015-08-14 2015-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,606 -4,472 -15.38 320 -36.63 0.0002
2015-05-14 2015-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 29,078 -27 -0.09 505 16.36 0.0003
2015-02-06 2014-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 29,105 -15 -0.05 434 -35.32 0.0003
2014-11-13 2014-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 29,120 0 0.00 671 -27.77 0.0005
2014-08-08 2014-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 29,120 29,120 929 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.